Terms: = Prostate cancer AND FOXP3, AIID, DIETER, IPEX, JM2, PIDX, XPID AND Prognosis
13 results:
1. Immune Evasion and Drug Resistance Mediated by USP22 in cancer: Novel Targets and Mechanisms.
Guo J; Zhao J; Fu W; Xu Q; Huang D
Front Immunol; 2022; 13():918314. PubMed ID: 35935969
[TBL] [Abstract] [Full Text] [Related]
2. Galectin-3 inhibition with belapectin combined with anti-OX40 therapy reprograms the tumor microenvironment to favor anti-tumor immunity.
Sturgill ER; Rolig AS; Linch SN; Mick C; Kasiewicz MJ; Sun Z; Traber PG; Shlevin H; Redmond WL
Oncoimmunology; 2021 Mar; 10(1):1892265. PubMed ID: 33717655
[TBL] [Abstract] [Full Text] [Related]
3. The role of regulatory T cells in the pathogenesis and treatment of prostate cancer.
Karpisheh V; Mousavi SM; Naghavi Sheykholeslami P; Fathi M; Mohammadpour Saray M; Aghebati-Maleki L; Jafari R; Majidi Zolbanin N; Jadidi-Niaragh F
Life Sci; 2021 Nov; 284():119132. PubMed ID: 33513396
[TBL] [Abstract] [Full Text] [Related]
4. Characterizing CDK12-Mutated prostate cancers.
Rescigno P; Gurel B; Pereira R; Crespo M; Rekowski J; Rediti M; Barrero M; Mateo J; Bianchini D; Messina C; Fenor de la Maza MD; Chandran K; Carmichael J; Guo C; Paschalis A; Sharp A; Seed G; Figueiredo I; Lambros M; Miranda S; Ferreira A; Bertan C; Riisnaes R; Porta N; Yuan W; Carreira S; de Bono JS
Clin Cancer Res; 2021 Jan; 27(2):566-574. PubMed ID: 32988971
[TBL] [Abstract] [Full Text] [Related]
5. Expression of PD-L1 in tumor-associated nerves correlates with reduced CD8
Mo RJ; Han ZD; Liang YK; Ye JH; Wu SL; Lin SX; Zhang YQ; Song SD; Jiang FN; Zhong WD; Wu CL
Int J Cancer; 2019 Jun; 144(12):3099-3110. PubMed ID: 30537104
[TBL] [Abstract] [Full Text] [Related]
6. M2 macrophages and regulatory T cells in lethal prostate cancer.
Erlandsson A; Carlsson J; Lundholm M; Fält A; Andersson SO; Andrén O; Davidsson S
Prostate; 2019 Mar; 79(4):363-369. PubMed ID: 30500076
[TBL] [Abstract] [Full Text] [Related]
7. Tumor infiltrating T lymphocytes expressing foxp3, CCR7 or PD-1 predict the outcome of prostate cancer patients subjected to salvage radiotherapy after biochemical relapse.
Nardone V; Botta C; Caraglia M; Martino EC; Ambrosio MR; Carfagno T; Tini P; Semeraro L; Misso G; Grimaldi A; Boccellino M; Facchini G; Berretta M; Vischi G; Rocca BJ; Barone A; Tassone P; Tagliaferri P; Del Vecchio MT; Pirtoli L; Correale P
Cancer Biol Ther; 2016 Nov; 17(11):1213-1220. PubMed ID: 27791459
[TBL] [Abstract] [Full Text] [Related]
8. Treg-Mediated Immune Tolerance and the Risk of Solid cancers: Findings From EPIC-Heidelberg.
Barth SD; Schulze JJ; Kühn T; Raschke E; Hüsing A; Johnson T; Kaaks R; Olek S
J Natl Cancer Inst; 2015 Nov; 107(11):. PubMed ID: 26298011
[TBL] [Abstract] [Full Text] [Related]
9. The prognostic value of the stem-like group in colorectal cancer using a panel of immunohistochemistry markers.
Ong CW; Chong PY; McArt DG; Chan JY; Tan HT; Kumar AP; Chung MC; Clément MV; Soong R; Van Schaeybroeck S; Waugh DJ; Johnston PG; Dunne PD; Salto-Tellez M
Oncotarget; 2015 May; 6(14):12763-73. PubMed ID: 25906747
[TBL] [Abstract] [Full Text] [Related]
10. Characterization of the immunological microenvironment of tumour buds and its impact on prognosis in mismatch repair-proficient and -deficient colorectal cancers.
Zlobec I; Minoo P; Terracciano L; Baker K; Lugli A
Histopathology; 2011 Sep; 59(3):482-95. PubMed ID: 22034888
[TBL] [Abstract] [Full Text] [Related]
11. Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling.
Tan W; Zhang W; Strasner A; Grivennikov S; Cheng JQ; Hoffman RM; Karin M
Nature; 2011 Feb; 470(7335):548-53. PubMed ID: 21326202
[TBL] [Abstract] [Full Text] [Related]
12. Androgen deprivation boosts prostatic infiltration of cytotoxic and regulatory T lymphocytes and has no effect on disease-free survival in prostate cancer patients.
Sorrentino C; Musiani P; Pompa P; Cipollone G; Di Carlo E
Clin Cancer Res; 2011 Mar; 17(6):1571-81. PubMed ID: 21159885
[TBL] [Abstract] [Full Text] [Related]
13. Invasive front of colorectal cancer: dynamic interface of pro-/anti-tumor factors.
Zlobec I; Lugli A
World J Gastroenterol; 2009 Dec; 15(47):5898-906. PubMed ID: 20014453
[TBL] [Abstract] [Full Text] [Related]
